Paying for performance (P4P) provides financial incentives for providers to increase the use and quality of care. P4P can affect health care by providing incentives for providers to put more effort into specific activities, and by increasing the amount of resources available to finance the delivery ...of services. This paper evaluates the impact of P4P on the use and quality of prenatal, institutional delivery, and child preventive care using data produced from a prospective quasi-experimental evaluation nested into the national rollout of P4P in Rwanda. Treatment facilities were enrolled in the P4P scheme in 2006 and comparison facilities were enrolled two years later. The incentive effect is isolated from the resource effect by increasing comparison facilities’ input-based budgets by the average P4P payments to the treatment facilities. The data were collected from 166 facilities and a random sample of 2158 households. P4P had a large and significant positive impact on institutional deliveries and preventive care visits by young children, and improved quality of prenatal care. The authors find no effect on the number of prenatal care visits or on immunization rates. P4P had the greatest effect on those services that had the highest payment rates and needed the lowest provider effort. P4P financial performance incentives can improve both the use of and the quality of health services. Because the analysis isolates the incentive effect from the resource effect in P4P, the results indicate that an equal amount of financial resources without the incentives would not have achieved the same gain in outcomes.
more
This guidance note identifies strategic action for policy-makers and managers at the national, subnational and facility level to address these different challenges.
It provides guidance on care for use in resource-limited settings or in settings where families with sick young infants do not accept or cannot access referral care, but can be managed in outpatient settings by an appropriately trained health worker. The guideline seeks to provide programmatic guida...nce on the role of CHWs and home visits in identifying signs of serious infections in neonates and young infants.
more
Pharmaceutical regulators are at the forefront of ensuring that only safe and effective medicines are authorized and available in the market. This document builds on the recommendations in the above publication and has been prepared to specifically assist national medicines regulatory authorities to... understand the nature and extent of oxytocin quality issues and to provide key technical information and quality requirements for oxytocin products in dossier assessments. Furthermore, this document also presents recommendations on other regulatory actions needed to ensure that only quality-assured oxytocin products are authorized and made available to women.
more
Wird ständig aktualisiert
A handbook for district and health facility staff
3rd edition!Large File 17 MB!
La résistance aux antimicrobiens (ou RAM, cette abréviation étant est ici également employée en mode adjectif pour désigner les organismes « résistants aux antimicrobiens ») est une préoccupation majeure pour la santé publique mondiale et une question de sécurité san...itaire des aliments. Lorsque des pathogènes deviennent résistants aux agents antimicrobiens, ils peuvent présenter un risque plus important pour la santé découlant d’un éventuel échec thérapeutique, de la diminution de choix thérapeutiques et de la probabilité accrue d’apparition et de gravité de la maladie. Les problèmes en rapport avec la RAM sont liés de façon inhérente à l’usage des antimicrobiens dans tous les types d’environnements, y compris les utilisations humaines et non humaines. L'utilisation d’agents antimicrobiens dans la production alimentaire animale et végétale représente un facteur de risque important pour la sélection et la transmission de micro-organismes résistants aux antimicrobiens (micro-organismes RAM) et de déterminants de la résistance aux antimicrobiens (déterminants de la RAM) des animaux et des plantes alimentaires à l’humain par sa consommation d’aliments.
more
The WHO Guide on Oral Cholera Vaccines in Mass Immunization Campaigns provides guidance on the planning and implementation of oral cholera vaccine (OCV) campaigns. It covers key aspects such as when and where to use OCVs, vaccine specifications, and recommendations for use in endemic areas, outbreak... settings, and complex emergencies. The document outlines steps for macro- and micro-planning, logistics, budgeting, human resource allocation, and risk communication. It also highlights challenges, including cold chain management, vaccine supply, and community engagement, ensuring that vaccination campaigns are efficient and effective in reducing cholera outbreaks.
more
This short paper aims to identify key evidence gaps in our knowledge of livestock- and fisheries-linked antimicrobial resistance in the developing world, and to document on-going or planned research initiatives on this topic by key stakeholders.
The antimicrobial resistant (AMR) infections in anima...ls that are of most potential risk to human health are likely to be zoonotic pathogens transmitted through food, especially Salmonella and Campylobacter. In addition, livestock associated methicillin resistant Staphylococcus aureus (LA MRSA) and extended spectrum beta lactamase E. coli (ESBL E. coli) are emerging problems throughout the world.
more
Accessed on 22.03.2020
Le Gouvernement du Burkina Faso a pris en compte au niveau du deuxième axe stratégique du Plan National de Développement Economique et Social (PNDES) 2016 – 2020 la nécessité de développer des actions allant dans le sens de la mitigation de l’impact du VIH sur les... populations. Deux CSLS successifs couvrant les périodes 2001-2005 et 2006 – 2010 ont été mis en œuvre contribuant de manière significative à baisser et à stabiliser la progression de la pandémie, en ramenant le taux de séroprévalence de 7,17% en 1997 à 0.90% en fin 2014 selon les estimations de l’ONUSIDA. Malgré cette évolution positive, le Burkina Faso demeure en situation d’épidémie généralisée. Ce même rapport mentionne que le nombre de PVVIH est estimé à 110.000, dont 57.000 femmes. 75.000 enfants sont estimés orphelins du fait du Sida. L’EDS IV réalisée en 2010 note que la prévalence en population générale présente des disparités selon le sexe. En effet, les femmes ont une prévalence de 1.2% contre 0.8% chez les hommes d’où un ratio H/F de 1.5 confirmant ainsi la théorie de la féminisation de l’infection pour des raisons à la fois socio-économiques et biologiques. Une étude récente conduite par le SP/CNLS ciblant les travailleuses du sexe (TS) a montré une prévalence au VIH de 16,19%, c’est à dire plus de 16 fois celle en population générale.
more
Supply of essential medicines and health technologies (6 April 2020)
This paper is one of a set of technical guidance papers developed by the WHO Regional Office for Europe to provide practical information and resources for decision-makers on measures to strengthen the health system response to C...OVID-19.
The purpose of this paper is to provide WHO Regional Office for Europe Country Offices and Member States with guidance on how to maintain supplies of medicines and health technologies, including devices, diagnostics and blood products, during the COVID-19 outbreak.
more
Urban poor communities including the homeless, residents of informal settlements, residents at risk of being evicted, Internally Displaced Persons (IDPs), undocumented persons, low-income renters, as well as homeowners are perhaps at greatest risk from both COVID-19 and the response interventions to... it.
more